Vaxcyte, Inc. (PCVX) Dividend History

Vaxcyte, Inc. is a biotechnology company focused on developing next-generation vaccines aimed at preventing infectious diseases. Leveraging its proprietary conjugation platform, Vaxcyte develops innovative vaccines primarily targeting pneumococcal disease, with the goal of providing broader coverage and improved immune responses compared to existing options.

825 Industrial Road, Ste. 300, San Carlos, CA, 94070
Phone: 650-837-0111
Website: https://www.vaxcyte.com

Dividend History

Vaxcyte, Inc. currently does not pay dividends

Company News

Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine

Vaxcyte has selected the VAX-24 Mid-dose as the basis for advancing an optimized dose formulation to a potential Phase 3 program. The company plans to initiate an infant Phase 3 study with either VAX-24 or VAX-31 pending the VAX-31 infant Phase 2 study topline data results anticipated in mid-2026.

Benzinga

Featured Companies: PFE
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

Kuehn Law, a shareholder litigation law firm, is investigating potential self-dealing by officers and directors of Vaxcyte, Inc. Shareholders may be entitled to damages and corporate governance reforms.

GlobeNewswire Inc.
Trump and Interest Rates: The 2 Key Reasons This Vanguard ETF Could Thrive in 2025

The Vanguard Russell 2000 ETF (VTWO) could be a great investment opportunity in 2025 due to potential benefits from the incoming Trump administration's policies and further interest rate cuts from the Federal Reserve.

The Motley Fool

Featured Companies: AIT SFM VTWO
Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know

Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research

Page data last updated 07/23/2025 01:32:01 UTC